Eckert & Ziegler acquires remaining Shares in EURO-PET Berlin Zyklotron
In the course of a consolidation of minority shareholding and the simplification of the corporate organisation Eckert & Ziegler Strahlen- und Medizintechnik AG takes over the remaining 30% shares of senior shareholders of EURO-PET Berlin Zyklotron GmbH Berlin (EURO-PET) and several shareholder loans. The pharmaceutical company on the premises of the scientific campus Adlershof which specialises in the production of short-lived isotopes for nuclear imaging thus becomes a 100% affiliate of Eckert & Ziegler AG. EURO-PET remains affiliated to its senior shareholders by co-operations in sales and the licensing of new drugs which were agreed upon in the scope of the assignment of the interests.
With the complete takeover of EURO-PET Eckert & Ziegler intends to continue to boost its position on the growing market for radioactive pharmaceutical products. The Holding already has a number of radiopharmaceutical production locations in Germany and markets the approved product Yttriga®, a preliminary stage of many radiotherapy treatments, as well as fluorine-18-based radiodiagnostic compounds for nuclear medical imaging (PET). In addition, Eckert & Ziegler supplies nuclear-imaging facilities around the world with synthesis technology and gallium-68 radionuclide generators.
Other news from the department business & finance
